June 08, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
NLRP3 inhibitor reduces inflammatory biomarkers in high-risk patients
A novel NLRP3 inhibitor reduced high-sensitivity C-reactive protein and other inflammatory biomarkers in patients at high inflammatory risk, according to the results of a trial presented at the European Atherosclerosis Society Congress. The NLRP3 inhibitor, ruvonoflast (NodThera), “is designed to directly inhibit activation of the NLRP3 inflammasome in multiple clinically relevant cell
751 words~3 min read
